HomeCompareLJPC vs JEPI

LJPC vs JEPI: Dividend Comparison 2026

LJPC yields 32.31% · JEPI yields 8.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LJPC wins by $122.1K in total portfolio value
10 years
LJPC
LJPC
● Live price
32.31%
Share price
$6.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$151.1K
Annual income
$21,317.26
Full LJPC calculator →
JEPI
JPMorgan Equity Premium Income ETF
● Live price
8.40%
Share price
$56.68
Annual div
$4.76
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$1,528.62
Full JEPI calculator →

Portfolio growth — LJPC vs JEPI

📍 LJPC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLJPCJEPI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LJPC + JEPI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LJPC pays
JEPI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LJPC
Annual income on $10K today (after 15% tax)
$2,746.37/yr
After 10yr DRIP, annual income (after tax)
$18,119.67/yr
JEPI
Annual income on $10K today (after 15% tax)
$714.16/yr
After 10yr DRIP, annual income (after tax)
$1,299.33/yr
At 15% tax rate, LJPC beats the other by $16,820.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LJPC + JEPI for your $10,000?

LJPC: 50%JEPI: 50%
100% JEPI50/50100% LJPC
Portfolio after 10yr
$90.0K
Annual income
$11,422.94/yr
Blended yield
12.69%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LJPC buys
0
JEPI buys
0
No recent congressional trades found for LJPC or JEPI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLJPCJEPI
Forward yield32.31%8.40%
Annual dividend / share$2.00$4.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$151.1K$29.0K
Annual income after 10y$21,317.26$1,528.62
Total dividends collected$106.0K$11.7K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: LJPC vs JEPI ($10,000, DRIP)

YearLJPC PortfolioLJPC Income/yrJEPI PortfolioJEPI Income/yrGap
1← crossover$13,931$3,231.02$11,260$840.19+$2.7KLJPC
2$19,113$4,206.67$12,641$907.94+$6.5KLJPC
3$25,845$5,393.83$14,150$978.20+$11.7KLJPC
4$34,470$6,816.44$15,795$1,050.85+$18.7KLJPC
5$45,380$8,496.64$17,584$1,125.74+$27.8KLJPC
6$59,010$10,453.99$19,526$1,202.74+$39.5KLJPC
7$75,846$12,704.70$21,628$1,281.69+$54.2KLJPC
8$96,416$15,261.03$23,898$1,362.43+$72.5KLJPC
9$121,296$18,130.84$26,347$1,444.79+$94.9KLJPC
10$151,104$21,317.26$28,982$1,528.62+$122.1KLJPC

LJPC vs JEPI: Complete Analysis 2026

LJPCStock

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. As of August 22, 2022, La Jolla Pharmaceutical Company operates as a subsidiary of Innoviva, Inc.

Full LJPC Calculator →

JEPIETF

The fund seeks to provide the majority of the returns associated with its primary benchmark, the Standard & Poor's 500 Total Return Index (S&P 500 Index), while exposing investors to less risk through lower volatility and still offering incremental income. Under normal circumstances, the fund invests at least 80% of its assets in equity securities. It may also invest in other equity securities not included in the S&P 500 Index.

Full JEPI Calculator →
📬

Get this LJPC vs JEPI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LJPC vs SCHDLJPC vs OLJPC vs KOLJPC vs MAINLJPC vs JEPQLJPC vs XYLDLJPC vs DIVOLJPC vs QYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.